IP Library › Granted Patent US 12,576,029
Granted Patent B2
US 12,576,029 · App. 18/221,262 · Granted Mar 17, 2026

Noncompetitive receptor-targeted vaccine delivery to plasmacytoid dendritic cells

Inventors: Shiva Kumar Jai Simha Rudra (St. Louis, MO); Zoe Clapacs (St. Louis, MO)
Assignee: Washington University
A61K9/1271A61K9/5161
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,029
App. No.
18/221,262
Granted
Mar 17, 2026
Kind
B2
Abstract

Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

Claims (14)

1 . A composition comprising liposomes, wherein the liposomes comprise gambogic acid-polyethylene glycol (PEG)-1,2-distearoyl-sn-glycero-3-phosphorylethanolamine (GA-PEG-DSPE).

2 . The composition of claim 1 , wherein the gambogic acid moiety enhances delivery of the liposomes to plasmacytoid dendritic cells.

3 . The composition of claim 2 , wherein the delivery of the liposomes to plasmacytoid dendritic cells is enhanced by at least by 25% compared to liposomes without the targeting moiety.

4 . The composition of claim 1 , wherein the liposomes further comprises a therapeutic agent or a diagnostic agent.

5 . The composition of claim 4 , wherein the therapeutic agent or diagnostic agent is a nucleic acid, an antiviral agent, an antibacterial agent, an antifungal agent, an antimetabolic agent, an anticancer agent, anti-inflammatory agent, a polypeptide, a protein, or an imaging agent.

6 . The composition of claim 1 , wherein the gambogic acid moiety binds to CD71 non-competitively with a natural ligand of CD71.

7 . The composition of claim 1 , wherein the gambogic acid moiety binds to CD71 non-competitively with transferrin.

8 . The composition of claim 1 , wherein the polyethylene glycol (PEG) moiety in the GA-PEG-DSPE has a molecular weight from about 750 Daltons to about 20,000 Daltons.

9 . The composition of claim 8 , wherein the PEG moiety has a molecular weight of from about 1000 Daltons to about 5000 Daltons.

10 . The composition of claim 9 , wherein the PEG moiety has a molecular weight of 2000 Daltons.

11 . The composition of claim 10 , wherein the GA-PEG-DSPE comprises a 1,2,3-triazole group.

12 . The composition of claim 11 , wherein the GA-PEG-DSPE has been made by reaction of alkyne-modified GA with azide-modified DSPE in a Cu (I) catalyzed click ligation.

13 . A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

14 . A method of comprising administering an effective amount of the composition of claim 1 to a subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2026
From: SIMHA RUDRA, SHIVA KUMAR JAI; CLAPACS, ZOE
To: WASHINGTON UNIVERSITY
Reel/Frame 073814/0232 →
Continuity (2)
Provisional Application 63388430 · Jul 12, 2022
Related Publication 20240024238A1 · Jan 25, 2024
References Cited (13)
US 10786465B2 · Majeti · 2020 [cited by examiner]
US 20070116753A1 · Hong · 2007 [cited by examiner]
US 20100069426A1 · Zale · 2010 [cited by examiner]
US 20170296639A1 · Ma · 2017 [cited by examiner]
US 20180312536A1 · Sakamuri · 2018 [cited by examiner]
US 20190343965A1 · De Berardinis · 2019 [cited by examiner]
Annie-Louise Robson et al. “Advantages and Limitations of Current Imaging Techniques for Characterizing Liposome Morphology.” Frontiers in Pharmacology, vol. 9, Article 80, Feb. 2018, pp. 1-8. (Year: 2018). [cited by examiner]
Joseph A. Katakowski et al. “Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses.” Molecular Therapy, vol. 24, No. 1, Jan. 2016, pp. 146-155 and 2 pages of supplem… [cited by examiner]
Maria Gregori et al. “Novel Antitransferrin Receptor Antibodies Improve the Blood-Brain Barrier Crossing Efficacy of Immunoliposomes.” Journal of Pharmaceutical Sciences, vol. 105, 2016, pp. 276-283 and 4 pages of suppl… [cited by examiner]
Elham Hatami, Meena Jaggia, Subhash C. Chauhan, Murali M. Yallapu. “Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.” BBA—Reviews on Cancer, vol. 1874, 2020, 188381, pp. 1-16. (Year: 20… [cited by examiner]
Ying Ji, Shuo Shan, Mingyu He, Chih-Chang Chu. “Inclusion complex from cyclodextrin-grafted hyaluronic acid and pseudo protein as biodegradable nano-delivery vehicle for gambogic acid.” Acta Biomaterialia, vol. 62, 2017… [cited by examiner]
Ravi Doddapaneni, Ketan Patel, Ibtisam Hasan Owaid, and Mandip Singh. “Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer.” Drug Delivery, vol.… [cited by examiner]
Horisberger, Michel Andre & Di Marco, Stefania, “Interferon-alpha hybrids,” Pharmacology & Therapeutics, 1995, vol. 66, issue 3, pp. 507-534. [cited by applicant]